Close Menu


The firm is developing tests combining biomarkers and other clinical measures to diagnose and monitor patients and identify those at risk of long-term effects.

By ending the agreement, Quanterix regains full control over its Simoa immunoassay technology and its potential use for in vitro diagnostic purposes.

The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.

The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.

Neurofilament light protein may be able to determine when an athlete who's suffered a concussion can safely return to playing again, researchers said.

The effort will use Quanterix's Simoa technology and will focus initially on development of an assay for measuring the liver toxicity biomarker microRNA-122.

Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.

The company posted Q4 revenues of $6.6 million, down from $6.7 million in Q4 2016 and shy of the consensus Wall Street estimate of $6.7 million.

The test from Banyan Biomarkers called the Brain Trauma Indicator measures the levels of the proteins UCH-L1 and GFAP that are released into the blood.

Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.